(Q40192467)

18 September 2017

1 reference

title

In vitro activity of imipenem--a review (English)

1 reference

18 September 2017

I Braveny

1

1 reference

18 September 2017

1 October 1984

1 reference

European journal of clinical microbiology

18 September 2017

1 reference

18 September 2017

3

1 reference

18 September 2017

456-462

1 reference

18 September 2017

5

1 reference

In vitro susceptibility of methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains to N-formimidoyl thienamycin

18 September 2017

1 reference

https://api.crossref.org/works/10.1007%2FBF02017375

Comparative activities of 13 beta-lactam antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02017375

Antibacterial activities of a new stabilized thienamycin, N-formimidoyl thienamycin, in comparison with other antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02017375

In vitro activity of N-formimidoyl thienamycin in comparison with cefotaxime, moxalactam, and ceftazidime

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02017375

In vitro activity of N-formimidoyl thienamycin (MK0787).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02017375

In Vitro Comparison of N -Formimidoyl Thienamycin, Piperacillin, Cefotaxime, and Cefoperazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02017375

In vitro activity of N-formimidoyl thienamycin (MK0787), a crystalline derivative of thienamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02017375

Comparative in vitro activity of N-formimidoyl thienamycin against gram-positive and gram-negative aerobic and anaerobic species and its beta-lactamase stability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02017375

Susceptibility of Gram-Positive Cocci to Various Antibiotics, Including Cefotaxime, Moxalactam, and N -Formimidoyl Thienamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02017375

A comparison of the antibacterial activities of N-formimidoyl thienamycin (MK0787) with those of other recently developed beta-lactam derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02017375

In vitro activity of N-formimidoyl thienamycin (MK0787) against resistant strains of Pseudomonas aeruginosa, Staphylococcus epidermidis, Serratia marcescens, and Enterococcus spp

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02017375

Susceptibility of Neisseria meningitidis and Neisseria gonorrhoeae isolates to N-formimidoyl thienamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02017375

Activities of eight new beta-lactam antibiotics and seven antibiotic combinations against Neisseria meningitidis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02017375

Comparative In Vitro Activities of N -Formimidoyl Thienamycin and Moxalactam Against Nonfermentative Aerobic Gram-Negative Rods

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02017375

Comparative in vitro susceptibilities of anaerobic bacteria to cefmenoxime, cefotetan, and N-formimidoyl thienamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02017375

In vitro activity of MK0787 (N-formimidoyl thienamycin) and other beta-lactam compounds against Bacteroides spp

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02017375

Susceptibilities of anaerobic bacteria to N-formimidoyl thienamycin (MK0787) and to other antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02017375

N-formimidoyl thienamycin (MK0787): in vitro activity against anaerobic bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02017375

In vitro susceptibility of Campylobacter fetus subsp. jejuni to N-formimidoyl thienamycin, rosaramicin, cefoperazone, and other antimicrobial agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02017375

In vitro activity of N-formimidoyl thienamycin against 98 clinical isolates of Brucella melitensis compared with those of cefoxitin, rifampin, tetracycline, and co-trimoxazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02017375

Activity of imipenem on aerobic bacteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02017375

In vitro susceptibility of Nocardia asteroides to N-formimidoyl thienamycin and several cephalosporins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02017375

Susceptibility of Nocardia asteroides to various antibiotics, including newer beta-lactams, trimethoprim-sulfamethoxazole, amikacin, and N-formimidoyl thienamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02017375

Susceptibility of enterococci and Listeria monocytogenes to N-Formimidoyl thienamycin alone and in combination with an aminoglycoside

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02017375

In vitro susceptibility of Mycobacterium fortuitum to N-formimidoyl thienamycin and several cephamycins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02017375

In vitro activity of N-formimidoyl thienamycin and other beta-lactam antibiotics against methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02017375

In vitro susceptibility patterns of methicillin-resistant and-susceptible Staphylococcus auerues strains in a population of parenteral drug abusers from 1972 to 1981.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02017375

Subinhibitory concentrations of imipenem induce increased resistance to methicillin and imipenem in vitro in methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02017375

Occurrence and expression of imipemide (N-formimidoyl thienamycin) resistance in clinical isolates of coagulase-negative staphylococci.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02017375

Lack of in vivo and in vitro bactericidal activity of N-formimidoyl thienamycin against enterococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02017375

Susceptibility of pneumococci to 14 beta-lactam agents: comparison of strains resistant, intermediate-resistant, and susceptible to penicillin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02017375

In vitro comparison of N-formimidoyl thienamycin (MK0787) and Azlocillin with three aminoglycosides and ticarcillin against Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02017375

Activities of New Beta-Lactam Antibiotics Against Isolates of Pseudomonas aeruginosa from Patients with Cystic Fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02017375

N-formimidoyl thienamycin (MK0787): in vitro study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02017375

In vitro activity of new beta-lactam antibiotics and other antimicrobial drugs against anaerobic isolates from obstetric and gynecological infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02017375

Effect of N-formimidoyl thienamycin (MK0787) on beta-lactamases and activity against beta-lactamase-producing strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02017375

Influence of inoculum size on activity of cefoperazone, cefotaxime, moxalactam, piperacillin, and N-formimidoyl thienamycin (MK0787) against Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02017375

MK0787 (N-formimidoyl thienamycin): evaluation of in vitro and in vivo activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02017375

In vitro activity of N-formimidoyl thienamycin, moxalactam, and other new beta-lactam agents against Bacteroides fragilis: contribution of beta-lactamase to resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02017375

In vitro evaluation of N-formimidoyl thienamycin (MK0787) combined with amikacin against gram-negative bacilli and Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02017375

Synergism between N-formimidoyl thienamycin and gentamicin or tobramycin against enterococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02017375

Imipenem antagonism of the in vitro activity of piperacillin against Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02017375

Susceptibility of Legionella spp. to imipenem and 27 other beta-lactam antibiotics.

21 January 2018

1 reference

12 December 2020

Susceptibility of anaerobic bacteria to imipenem.

1 reference

12 December 2020

The semi-synthetic thienamycin derivative MK0787 and its properties with respect to a range of beta-lactamases from clinically relevant bacterial species

1 reference

12 December 2020

Antibacterial activity of N-formimidoyl thienamycin in comparison with cefotaxime, lamoxactam, cefoperazone, piperacillin gentamicin

1 reference

12 December 2020

N-formimidoyl-thienamycin a novel beta-lactam: an in-vitro comparison with other beta-lactam antibiotics

1 reference

12 December 2020

In-vitro activity of MK0787 (N-formimidoyl thienamycin) against Pseudomonas aeruginosa and other Gram-negative organisms and its stability to their beta-lactamases

1 reference

12 December 2020

Susceptibility of Mycobacterium fallax to imipenem and twenty other antimicrobial agents

1 reference

12 December 2020

Cefoperazone against carbenicillin-resistant isolates of Pseudomonas aeruginosa: comparison with other newer cephalosporins and N-formimidoyl thienamycin

1 reference

12 December 2020

Comparative activity of imipenem (N-formimidoyl thienamycin) on enterococci and its interactions with aminoglycosides

1 reference

12 December 2020

In vitro comparative activity of moxalactam, GR 20263, and N-formimidoyl thienamycin to other beta-lactam antibiotics and tobramycin against enterobacteriaceae and staphylococci

1 reference

12 December 2020

The comparative activities of N-formimidoyl thienamycin (MK0787), moxalactam, cefotaxime and cefoperazone against Yersinia enterocolitica and Listeria monocytogenes

1 reference

12 December 2020

In-vitro antagonism by N-formimidoyl thienamycin and cefoxitin of second and third generation cephalosporins in Aeromonas hydrophila and Serratia marcescens

1 reference

12 December 2020

Comparative susceptibilities of penicillin-resistant pneumococci to co-trimoxazole, vancomycin, rifampicin and fourteen beta-lactam antibiotics

1 reference

12 December 2020

The in vitro activity of N-formimidoyl thienamycin compared with other broad-spectrum cephalosporins and with clindamycin and metronidazole.

1 reference

12 December 2020

The activity of N-formimidoyl thienamycin (MK0787) against Haemophilus influenzae and Streptococcus pneumoniae

1 reference

12 December 2020

N-Acetimidoyl- and N-formimidoylthienamycin derivatives: antipseudomonal .beta.-lactam antibiotics

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF02017375

1 reference

18 September 2017

1 reference

PubMed ID

6389125